EARLY FEASIBILITY STUDY: SAFETY AND EFFICACY OF PHOTON INFUSION SET
NCT06684561 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2024-11-12
Summary
Study 1:
The purpose of this study is to evaluate safety and efficacy of Photon infusion sets (PIS) with new PFAS-free cannula (catheter) in adult patients with Type 1 diabetes for up to 10 days and 6 hours.
This is a 1-center, prospective, open-label, 1-arm study with type 1 patients with diabetes on 780G insulin pump therapy with Guardian™ 4 Continuous Glucose Monitoring (CGM). All subjects will be instructed to change infusion sets every 246 hours (10 days \& 6 hours) or at set failure. Each subject is required to wear the CGM device continuously.
After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of \<6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study.
Photon infusion sets with 6-mm and 9-mm cannula length will be supplied for this study, with selection based on subjects' needs and doctor's recommendation. Subjects will change insulin reservoirs at least every 7 days (the labelled wear duration of the Extended reservoir). The infusion set(s) or reservoir(s) can be replaced independent of each other. The date and time of each infusion set insertion will be recorded in a Daily Log (Diary) which will include the causes of early removal, if occurs.
Study 2: If Study 1 is successful, the same study designed as illustrated in Figure 1 may be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users.
Conditions
- Type 1 Diabetes Mellitus
Interventions
- DEVICE
-
PIS
All subjects will be instructed to change the investigational infusion sets (PIS) every 246 hours (10 days \& 6 hours) or at set failure. Each subject is required to wear the CGM device continuously. defined as any one of the following: After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of \<6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study. if study 1 is successful, participants will enter study 2; , the same study designed will be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users
Sponsors & Collaborators
-
Sheba Medical Center
lead OTHER_GOV
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-31
- Primary Completion
- 2025-12-31
- Completion
- 2026-04-30
More Related Trials
-
Evaluation of Medtronic DUO Extended Set
NCT04823312 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
NCT05544643 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")
NCT04398030 ·Status: COMPLETED ·Phase: NA
-
Clinical Study on the Treatment of Type 1 Diabetes With CNK-UT009 Cell Injection
NCT07051564 ·Status: RECRUITING ·Phase: NA
-
"FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)
NCT04503564 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes
NCT04481243 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Feasibility of an Insulin Sensitivity-Informed Bolus Calculator in Type 1 Diabetes
NCT03709108 ·Status: COMPLETED ·Phase: NA
-
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
NCT00287066 ·Status: TERMINATED ·Phase: PHASE3
-
Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections
NCT02465411 ·Status: COMPLETED ·Phase: NA
-
The isCGM Use and Hypoglycemic Episodes and Fear of Hypoglycemia in Newly Diagnosed Type 1 Diabetes
NCT06414824 ·Status: TERMINATED ·Phase: NA
-
A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes
NCT07126873 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes
NCT01536431 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France
NCT07048795 ·Status: RECRUITING
-
Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set
NCT02687256 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of CSII and CGM on Progression of Late Diabetic Complications
NCT01454700 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Physician-based Decision Support
NCT03443713 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
NCT04113694 ·Status: COMPLETED ·Phase: NA
-
Feasibility Study of an Integrated Sensor and Infusion Set
NCT01770561 ·Status: COMPLETED ·Phase: NA
-
Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use
NCT02137512 ·Status: COMPLETED ·Phase: NA
-
The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.
NCT04308291 ·Status: COMPLETED
-
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus
NCT01185496 ·Status: COMPLETED
-
Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy
NCT01104142 ·Status: COMPLETED
-
A Pilot Study to Assess the Safety, PK and PD of Insulin Injected Via MicronJet or Conventional Needle
NCT00602914 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
NCT05791201 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
NCT02411578 ·Status: COMPLETED ·Phase: PHASE2